What were the total revenues and how do they compare to the same quarter last year? | TXMD (Aug 12, 2025) | Candlesense
TXMD

What were the total revenues and how do they compare to the same quarter last year?

Answer

The press release for TherapeuticsMD’s second‑quarter 2025 results does not disclose a revenue figure for the three months ended June 30 2025. It only reports net income from continuing operations of $545 thousand (or $0.05 per share) versus a net loss of $1.05 million (or $(0.09) per share) in the same quarter a year earlier. Because total revenue is not disclosed in the provided excerpt, we cannot calculate or compare the quarter‑over‑quarter revenue performance.

Trading implication

Without a revenue number, the focus for traders must shift to the swing from a loss to a modest profit and the per‑share earnings improvement. This earnings turnaround could be a catalyst for short‑term upside if the market perceives the shift as a sign of improving cash‑flow generation, especially given TXMD’s royalty‑based business model. However, the lack of revenue visibility means any price move remains speculative until the full earnings release (including the top‑line figures) is reviewed. Until those details are available, a cautious stance—perhaps waiting for the complete filing or monitoring subsequent guidance—may be prudent.

Other Questions About This News

What is the company's guidance on capital expenditures for the remainder of 2025? How does the $0.05 EPS from continuing operations compare to analyst consensus estimates? What drove the swing from a $1.05 million loss to a $545 k profit? What is the company's cash and cash equivalents balance after Q2? Did TherapeuticsMD provide any guidance for Q3 or full‑year 2025 earnings? What are the projected royalty income streams for the next 12‑18 months? Are there any upcoming royalty or licensing agreements that could affect future cash flows? How does the net margin for the quarter compare to prior quarters and industry peers? What are the key risks highlighted in the MD&A that could impact future earnings? How does the current valuation (P/E, EV/EBITDA) compare to other royalty‑focused pharma companies? What is the company's debt level and any upcoming maturities? Did the company announce any share buyback or dividend plans? What is the impact of the results on the stock’s technical indicators (e.g., moving averages, RSI)? Are there any pending regulatory or legal matters that could affect the company’s cash flow? How does the earnings per share compare on a diluted basis versus basic? What is the outlook for the company's key royalty assets (e.g., patent expirations, new product launches)? How does the net income from continuing operations compare to net income from discontinued operations? Is there any indication of a potential acquisition or partnership in the pipeline? What is the expected impact of macro‑economic trends on the company’s royalty revenue?